Layer 1
它是什麼What is it?
辨認胜肽、荷爾蒙、受體、促分泌劑與細胞療法，不把不同技術混為一談。Identify peptides, hormones, receptors, secretagogues, and cell therapies without conflating distinct technologies.
Zero-to-literate learning kit
胜肽、表現與ProtocolsPeptides, Performance, and Protocols
從一集2小時以上的前沿健康對談，走到能分辨「人體機制、個人經驗、臨床證據與行銷話術」的完整入門課。先讀原創雙語對話，再依4週路線建立判讀能力。A complete beginner course that moves from a frontier-health conversation lasting more than two hours to distinguishing human mechanisms, personal experience, clinical evidence, and marketing language. Start with the original bilingual dialogue, then build appraisal skills through the four-week path.
重要限制與醫療聲明Important limitations and medical disclaimer
本文件不是影片逐字稿或逐句翻譯，而是依節目主題重新撰寫的原創教學對話；此作法避免重製未由使用者提供的受著作權逐字內容。內容僅供學習，不構成診斷、處方、用藥、注射、運動治療或停藥建議。尤其不要依節目、社群貼文或本教材自行取得與施打胜肽、荷爾蒙、迷幻藥物或細胞製品。This document is not a transcript or line-by-line translation of the video. It is an original teaching dialogue rewritten around the episode’s themes, which avoids reproducing copyrighted verbatim material that the user did not provide. It is for learning only and is not advice on diagnosis, prescribing, medication, injection, exercise therapy, or stopping treatment. In particular, do not obtain or inject peptides, hormones, psychedelic drugs, or cell products on your own based on the episode, social-media posts, or this course.
0
你真正要學的是判讀框架What you are really learning is an appraisal framework
不是背一串化合物名稱，而是知道每個主張站在哪一層。It is not memorizing a list of compound names; it is knowing what level each claim occupies.
Layer 2
如何作用How might it work?
把「可能的機制」當作研究起點，而不是把生物學合理性直接當成療效。Treat a plausible mechanism as the starting point for research, not as proof of clinical benefit.
Layer 3
證據多強How strong is the evidence?
分辨個案、動物研究、早期人體試驗、隨機對照試驗、核准標示與指引。Distinguish case reports, animal studies, early human trials, randomized controlled trials, approved labeling, and guidance.
Layer 4
決策是否合理Is the decision reasonable?
把適應症、替代方案、產品品質、風險、可逆性與監測一起評估。Assess indication, alternatives, product quality, risk, reversibility, and monitoring together.
1
原創雙語節目對話Original bilingual programme dialogue
一行英文、一行正體中文。角色為「Host」與「Science Guide」，不是Tim Ferriss或Andrew Huberman的逐字發言。One English line and one Traditional Chinese line. The speakers are “Host” and “Science Guide,” not verbatim statements by Tim Ferriss or Andrew Huberman.
Scene 1｜能量、競爭與表現Energy, competition, and performance
影片約02:03起Video from about 02:03Host
Let us begin with a basic question: what does human performance actually mean?
先從一個基本問題開始：所謂人類表現，究竟是什麼？
Science Guide
Performance is not one trait. It is the interaction of skill, energy, attention, recovery, and context.
表現不是單一特質，而是技能、能量、注意力、恢復與情境的交互作用。
Host
Can competition improve performance?
競爭能提升表現嗎？
Science Guide
Sometimes, but it can also misdirect attention toward comparison instead of the task.
有時可以，但競爭也可能讓注意力離開任務本身，轉向與他人比較。
Host
So motivation and output are not the same thing.
所以，動機與實際產出並不是同一件事。
Science Guide
Exactly. A strong emotional drive can create focus, but it can also create reckless decisions.
沒錯。強烈情緒驅力可能帶來專注，也可能導致魯莽決策。
Scene 2｜高強度、低訓練量與失敗訓練High intensity, low volume, and training to failure
影片約06:27起Video from about 06:27Host
The episode describes very hard resistance training with relatively few working sets. Is that the universal best method?
節目談到工作組數較少、但強度極高的阻力訓練。這是所有人最好的方法嗎？
Science Guide
No. It is one method, shaped by training history, technique, tolerance, and goals.
不是。它只是一種方法，效果會受到訓練史、動作技術、耐受度與目標影響。
Host
Does every set need to reach muscular failure?
每一組都必須做到肌肉力竭嗎？
Science Guide
The evidence does not show that failure is required for strength or muscle growth.
現有證據並不支持「增強肌力或肌肉量一定要做到力竭」。[S10]
Host
Then what should a beginner prioritize?
那初學者應該優先注意什麼？
Science Guide
Technique, gradual overload, enough recovery, and a program you can repeat safely.
動作技術、漸進增加負荷、充分恢復，以及能安全長期執行的課表。
Host
A dramatic workout can feel convincing even when it is not the best experiment.
一次很震撼的訓練會令人信服，但它不一定是最好的實驗。
Science Guide
Right. Soreness, exhaustion, and effectiveness are three different variables.
正是如此。痠痛、疲憊與有效性是三個不同變項。
Scene 3｜迷幻藥物與神經可塑性Psychedelic drugs and neuroplasticity
影片約31:12起Video from about 31:12Host
People often say that psychedelic drugs increase neuroplasticity. What does that phrase leave out?
人們常說迷幻藥物會增加神經可塑性。這句話遺漏了什麼？
Science Guide
Plasticity means the nervous system can change. It does not mean every change is useful, safe, or lasting.
可塑性表示神經系統可以改變，但不表示每種改變都有效、安全或持久。
Host
So opening a window for change is not the same as directing the change.
所以，打開改變的窗口，並不等於知道如何引導改變。
Science Guide
Correct. Context, expectations, support, follow-up, and trial design matter.
正確。情境、期待、支持、後續照護與試驗設計都很重要。
Host
Are MDMA and psilocybin ordinary self-help tools?
MDMA與裸蓋菇鹼是一般的自助工具嗎？
Science Guide
No. They remain investigational in federal drug development, with major safety, legal, and clinical-design constraints.
不是。它們在美國聯邦藥物開發架構下仍屬研究中產品，並涉及重大的安全、法律與臨床設計限制。[S12]
Scene 4｜皮質醇不是單純的敵人Cortisol is not simply the enemy
影片約01:00:27起Video from about 01:00:27Host
Why is cortisol usually described as something we should lower?
為什麼皮質醇通常被描述成需要降低的東西？
Science Guide
Because “stress hormone” is a memorable label, but it hides cortisol’s normal roles in metabolism, immune signaling, and adaptation.
因為「壓力荷爾蒙」是容易記住的標籤，卻掩蓋了皮質醇在代謝、免疫訊號與適應中的正常功能。
Host
Does one cortisol measurement tell us how stressed a person is?
一次皮質醇測量能告訴我們一個人的壓力程度嗎？
Science Guide
Usually not. Time of day, sampling method, acute events, illness, and medication can change the interpretation.
通常不能。採樣時段、採樣方法、急性事件、疾病與藥物都會改變解讀。[S11]
Host
The better question is not “Is cortisol bad?”
更好的問題不是「皮質醇是不是壞東西？」
Science Guide
It is “Is the pattern appropriate for the time, context, and person?”
而是「這個模式對此時段、情境與個人而言是否適當？」
Scene 5｜胜肽到底是什麼What exactly is a peptide?
影片約01:03:26起Video from about 01:03:26Host
The word peptide sounds like a single product category. Is it?
「胜肽」聽起來像單一產品類別。真的是嗎？
Science Guide
No. It describes chains of amino acids, not one clinical effect.
不是。它描述的是胺基酸鏈，不代表單一臨床效果。
Host
Can a peptide be both natural and a medicine?
胜肽可以同時是人體天然物質與藥物嗎？
Science Guide
Yes. The body uses peptide signals, and medicines can imitate, modify, block, or extend those signals.
可以。人體會使用胜肽訊號，而藥物可以模仿、修改、阻斷或延長這些訊號。
Host
Why does the route of administration matter?
為什麼給藥途徑很重要？
Science Guide
Many peptides are broken down in digestion, and different routes create different exposure, sterility, and dosing risks.
許多胜肽會在消化過程中被分解；不同給藥途徑會帶來不同的暴露、無菌與劑量風險。
Scene 6｜GLP-1、GH軸與「增強」誘惑GLP-1, the GH axis, and the lure of “enhancement”
影片約01:10:00起Video from about 01:10:00Host
GLP-1 drugs and experimental recovery peptides are often discussed together. Should they be evaluated together?
GLP-1藥物與實驗性恢復胜肽常被放在一起談。它們應該用同一標準評估嗎？
Science Guide
They should use the same evidence principles, but their evidence and regulatory status can be radically different.
應該採用相同的證據原則，但它們的證據量與監管狀態可能截然不同。
Host
What is the growth-hormone axis in one sentence?
用一句話說明生長激素軸是什麼？
Science Guide
It is a feedback-controlled signaling system connecting hypothalamic signals, pituitary growth hormone, and downstream IGF-1 activity.
它是連結下視丘訊號、腦下垂體生長激素與下游IGF-1活性的回饋控制系統。[S9]
Host
Does stimulating a natural pathway make an intervention natural or safe?
刺激天然路徑，就能讓介入變得天然或安全嗎？
Science Guide
No. “Uses your own pathway” says nothing about dose, product quality, off-target effects, or long-term risk.
不能。「使用你自身的路徑」並未交代劑量、產品品質、非目標效應或長期風險。
Scene 7｜BPC-157、Epitalon與「沒有副作用報告」BPC-157, Epitalon, and “no reported side effects”
影片約01:35:52起Video from about 01:35:52Host
Why is “no reported side effects” a weak safety claim?
為什麼「沒有副作用報告」是很弱的安全主張？
Science Guide
Because an absent report may reflect absent surveillance, small samples, short follow-up, or an uncertain product identity.
因為沒有報告，可能只是缺乏監測、樣本太小、追蹤太短，或產品身分本身就不明確。
Host
What does the FDA say about BPC-157 and several similar compounded peptides?
FDA如何看待BPC-157與數種相似的調製胜肽？
Science Guide
It identifies limited safety information and concerns such as immunogenicity, impurities, and product characterization.
FDA指出，相關安全資料有限，並存在免疫原性、雜質與產品鑑別等疑慮。[S5]
Host
Is a compounded drug simply a cheaper generic?
調製藥物只是比較便宜的學名藥嗎？
Science Guide
No. A generic is FDA-approved; a compounded product is not FDA-approved and is not reviewed in the same way before marketing.
不是。學名藥經FDA核准；調製產品未經FDA核准，上市前也不接受相同方式的審查。[S4]
Host
So “research use only” is not a hidden certificate of purity.
所以，「僅供研究使用」並不是隱藏版的純度證書。
Science Guide
Correct. It can be a warning that the product was never evaluated for personal medical use.
正確。它反而可能是在警告：產品從未經過個人醫療使用所需的評估。
Scene 8｜幹細胞、AI、穿戴裝置與生活ProtocolsStem cells, AI, wearables, and everyday protocols
影片約01:43:48起Video from about 01:43:48Host
Regenerative medicine sounds broad enough to include almost anything. What is the danger?
再生醫學聽起來廣泛到幾乎什麼都能包含。危險在哪裡？
Science Guide
The label can make an unapproved clinic product sound like an established therapy.
這個標籤可能讓未核准的診所產品聽起來像已建立的療法。
Host
What should we ask before believing a stem-cell claim?
相信幹細胞主張之前，我們應該問什麼？
Science Guide
What exactly is the product, what indication is claimed, what approval or trial oversight exists, and what harms have been reported?
產品究竟是什麼、聲稱用於哪個適應症、有哪些核准或試驗監督，以及已報告哪些傷害？[S14]
Host
Can wearables and AI solve the evidence problem?
穿戴裝置與AI能解決證據問題嗎？
Science Guide
They can collect and analyze more data, but a precise number is not automatically a valid clinical endpoint.
它們能收集與分析更多資料，但精密數字不會自動成為有效的臨床終點。[S15]
Host
Then what is the most durable protocol?
那最耐用的protocol是什麼？
Science Guide
Build a repeatable baseline, measure what matters, change one thing at a time, and use medical care when the question is medical.
建立可重複的基線、測量真正重要的結果、一次只改變一件事；問題屬於醫療時，就回到醫療照護。
2
4週零基礎學習路線A four-week learning path for beginners
每週3次、每次約35–50分鐘；先理解，再判讀，最後才談個人決策。Three sessions a week, about 35–50 minutes each: understand first, appraise next, and discuss personal decisions only last.
01建立語言Build the vocabulary
單元1–3：胜肽、受體、證據階梯。Modules 1–3: peptides, receptors, and the evidence hierarchy.
02理解人體Understand the body
單元4–6：訓練、可塑性、皮質醇。Modules 4–6: training, plasticity, and cortisol.
03拆解產品Deconstruct products
單元7–9：GLP-1、GH軸、灰色胜肽。Modules 7–9: GLP-1, the GH axis, and gray-market peptides.
04形成判斷Form a judgment
單元10–12：幹細胞、AI與決策清單。Modules 10–12: stem cells, AI, and a decision checklist.
每次學習循環The learning cycle for each session
- 先讀該單元，不查陌生詞。Read the module first without looking up unfamiliar terms.
- 再用術語表補齊概念。Then use the glossary to fill in the concepts.
- 用自己的話寫3句摘要。Write a three-sentence summary in your own words.
- 完成「一分鐘檢核」。Complete the “one-minute check.”
- 隔天不看教材重述一次。The next day, explain it once without looking at the course.
你應達到的終點Your intended endpoint
- 看到胜肽名稱時，先問狀態與證據，而不是先問效果。When you see a peptide name, ask about status and evidence before asking about effects.
- 能解釋為何機制、案例與臨床療效不是同一層。Explain why mechanisms, anecdotes, and clinical efficacy are not the same level of evidence.
- 能辨識調製、核准、仿冒與研究用產品的差異。Identify the differences among compounded, approved, counterfeit, and research-use products.
- 能把節目主張轉成可驗證問題。Turn programme claims into verifiable questions.
3
第一週｜基礎科學與證據Week 1: foundational science and evidence
先把語言弄清楚，後面才不會被名詞帶著走。Clarify the language first, so terminology does not lead you by the nose later.
單元1｜胺基酸、胜肽、蛋白質Module 1: amino acids, peptides, and proteins
學完你能做到By the end, you can用自己的話解釋胜肽是什麼，並知道「胜肽」不是療效名稱。Explain in your own words what a peptide is and know that “peptide” is not a name for efficacy.
可以把胺基酸想成字母、胜肽想成短句、蛋白質想成較長且折疊成立體結構的文章。這個比喻只用來入門；真實生物分子還涉及序列、立體形狀、電荷、修飾與環境。You can think of amino acids as letters, peptides as short sentences, and proteins as longer texts folded into three-dimensional structures. This analogy is only an introduction; real biomolecules also involve sequence, three-dimensional shape, charge, modification, and environment.
FDA在特定監管政策中，把由40個以下α-胺基酸組成的聚合物視為胜肽；這是監管操作定義，不是所有科學領域共同採用的唯一邊界。[S3]In specified regulatory policies, the FDA treats polymers of 40 or fewer α-amino acids as peptides. This is an operational regulatory definition, not the one universal boundary used across every scientific field.
1
第一個防錯規則：First error-prevention rule:分子類別不等於臨床用途。說某物「是胜肽」，就像說某物「是軟體」；你還不知道它做什麼、是否有效、是否合法或是否安全。A molecular category is not the same as a clinical use. Saying that something “is a peptide” is like saying that something “is software”; you still do not know what it does, whether it works, whether it is legal, or whether it is safe.
一分鐘檢核One-minute check
請不用看上文完成這句話：「胜肽是一種＿＿＿＿分類，不是一種＿＿＿＿證明。」參考答案：分子／療效或安全。Without looking above, complete this sentence: “A peptide is a ______ classification, not proof of ______.” Reference answer: molecular / efficacy or safety.
單元2｜訊號、受體與回饋Module 2: signals, receptors, and feedback
學完你能做到By the end, you can畫出「訊號→受體→細胞反應→回饋」的簡圖。Draw a simple diagram of “signal → receptor → cellular response → feedback.”
訊號Signal
人體分子攜帶訊息，例如「現在有營養」「需要動員能量」或「請釋放另一種荷爾蒙」。Molecules in the body carry messages, such as “nutrients are available now,” “mobilize energy,” or “release another hormone.”
受體Receptor
受體像具條件的接收器。分子能否結合、結合多久、在哪個組織結合，都會改變結果。A receptor is like a conditional receiver. Whether a molecule can bind, how long it binds, and in which tissue it binds all change the outcome.
回饋Feedback
許多內分泌系統會以負回饋限制輸出；外加刺激仍可能改變脈衝、濃度與下游反應。Many endocrine systems use negative feedback to limit output; an external stimulus can still alter pulses, concentrations, and downstream responses.
促效劑（agonist）An agonist會活化受體；拮抗劑（antagonist）An antagonist會阻擋或降低活化；促分泌劑（secretagogue）A secretagogue則促使身體釋放某種內源物質。三者不能混用。activates a receptor; an antagonist blocks or reduces activation; and a secretagogue prompts the body to release an endogenous substance. The three are not interchangeable.
2
第二個防錯規則：Second error-prevention rule:「刺激身體自己分泌」不等於無風險。自然路徑也可能被過度、錯時或不均勻地刺激。“Stimulating your body to secrete its own supply” does not mean risk-free. Natural pathways can also be stimulated excessively, at the wrong time, or unevenly.
一分鐘檢核One-minute check
若產品聲稱「不是荷爾蒙，只是促進你自己分泌」，還缺哪些資訊？至少包括：實際分子、受體、暴露量、時程、非目標效應、長期資料與產品品質。If a product claims, “It is not a hormone; it only encourages your own secretion,” what information is still missing? At minimum: the actual molecule, receptor, exposure, timing, off-target effects, long-term data, and product quality.
單元3｜證據階梯：從故事到可重複結論Module 3: the evidence hierarchy—from stories to repeatable conclusions
學完你能做到By the end, you can對任何健康主張標記「證據層級」與「尚未回答的問題」。Label the “evidence level” and “unanswered questions” for any health claim.
故事／案例Stories / cases
機制合理Plausible mechanism
細胞／動物Cells / animals
早期人體Early human studies
對照試驗Controlled trials
重複與整合Replication and synthesis
核准／指引Approval / guidance
3
第三個防錯規則：Third error-prevention rule:「有研究」不是結論。要問研究設計、對照、樣本、終點、效果量、持續時間、利益衝突與能否重複。“There is a study” is not a conclusion. Ask about design, controls, sample, endpoints, effect size, duration, conflicts of interest, and whether the result can be replicated.
一分鐘檢核One-minute check
一位名人說某胜肽讓舊傷在一週內改善。這最多屬於哪一層？答案：個人案例；它可以產生假說，不能單獨證明因果。A celebrity says a peptide improved an old injury within a week. What is the highest evidence level this reaches? Answer: an individual case; it can generate a hypothesis but cannot by itself establish causation.
4
第二週｜表現、可塑性與壓力Week 2: performance, plasticity, and stress
把「更強刺激」與「更好適應」拆開。Separate “stronger stimulus” from “better adaptation.”
單元4｜阻力訓練：刺激、疲勞、恢復Module 4: resistance training—stimulus, fatigue, and recovery
學完你能做到By the end, you can區分訓練方法、訓練目的與適應結果。Distinguish training method, training goal, and adaptation outcome.
阻力訓練先造成刺激，身體在後續恢復中產生適應。工作組數、負荷、動作選擇、每組距離力竭的程度、頻率、睡眠與營養共同決定刺激與疲勞。Resistance training first creates a stimulus; the body adapts during subsequent recovery. Working sets, load, exercise selection, proximity to failure, frequency, sleep, and nutrition jointly determine stimulus and fatigue.
節目中的高強度、低訓練量經驗可當作一種方法案例；它不能直接外推為新手處方。統合分析顯示，做到力竭並非力量或肌肥大進步的必要條件。[S10]Source S10美國身體活動指引對一般成人的基礎是每週至少2天肌力活動，而不是複製職業健美選手的極端做法。[S8]The episode’s high-intensity, low-volume experience is one method case; it cannot be directly generalized as a novice prescription. A meta-analysis finds that reaching failure is not required for strength or hypertrophy progress. General US guidance for adults is at least two days of muscle-strengthening activity each week, not copying an elite bodybuilder’s extreme routine.
| 概念Concept | 在問什麼Question being asked | 常見誤判Common misreading |
|---|---|---|
| 方法Method | 今天怎麼練？How will you train today? | 把名人課表當成普遍最佳解。Treating a celebrity routine as universally optimal. |
| 目的Goal | 要改善力量、肌肉量、耐力、技巧或健康？Are you trying to improve strength, muscle mass, endurance, skill, or health? | 未定目標就比較課表。Comparing routines before defining the goal. |
| 結果Outcome | 長期指標有沒有改善？Have long-term indicators improved? | 用單次痠痛或疲憊代替成效。Using one bout of soreness or exhaustion as a stand-in for results. |
一分鐘檢核One-minute check
請說出「訓練很痛苦，所以有效」的邏輯錯誤：把主觀刺激感與長期適應結果混為一談。Name the logical error in “training hurts a lot, so it works”: it conflates subjective intensity with long-term adaptation.
單元5｜神經可塑性：打開窗口不等於完成學習Module 5: neuroplasticity—opening a window is not completing learning
學完你能做到By the end, you can說明誘發可塑性、引導學習、鞏固與維持的差異。Explain the differences among inducing plasticity, directing learning, consolidation, and maintenance.
1
擾動Perturbation
新奇、錯誤、壓力或藥理作用可能改變原有神經活動。Novelty, error, stress, or pharmacological action may alter existing neural activity.
2
選擇Selection
注意力與情境影響哪些連結被強化。Attention and context influence which connections are strengthened.
3
鞏固Consolidation
休息、睡眠與重複有助於讓部分改變穩定。Rest, sleep, and repetition help some changes become stable.
4
泛化Generalization
要觀察改變能否跨情境、長期維持並改善重要生活結果。Observe whether changes transfer across contexts, persist over time, and improve important life outcomes.
迷幻藥物可能與神經可塑性研究相關，但「可塑性增加」不能單獨回答療效、安全、適用族群與照護模式。FDA的2026年最終指引特別處理試驗盲法、心理支持、劑量反應、安全監測與效果持久性等設計難題。[S12]Psychedelic drugs may be relevant to neuroplasticity research, but “more plasticity” alone cannot answer questions of efficacy, safety, eligible populations, or care model. The FDA’s 2026 final guidance addresses design challenges including trial blinding, psychological support, dose response, safety monitoring, and durability of effects.
一分鐘檢核One-minute check
為什麼神經可塑性不是天然的好事？因為神經系統也可能學會恐懼、成癮與不良反應；方向、情境與鞏固決定改變的價值。Why is neuroplasticity not inherently good? The nervous system can also learn fear, addiction, and maladaptive responses; direction, context, and consolidation determine the value of change.
單元6｜皮質醇：節律、情境與測量Module 6: cortisol—rhythm, context, and measurement
學完你能做到By the end, you can拒絕「皮質醇越低越好」的單軸思考。Reject the one-axis idea that lower cortisol is always better.
皮質醇由下視丘－腦下垂體－腎上腺軸（HPA axis）調節，參與能量供應、免疫訊號、血管張力與壓力反應。健康成人通常在接近醒來時較高，之後逐步下降；異常過高與過低都可能是問題。[S11]Cortisol is regulated by the hypothalamic-pituitary-adrenal axis and participates in energy supply, immune signaling, vascular tone, and stress response. It is usually higher near waking in healthy adults and then declines; both abnormally high and low values may be problems.
C
正確問題：The right question:不是「怎麼把皮質醇降到最低」，而是「測量是否可靠？日夜節律是否合理？症狀、疾病、藥物與情境如何解釋？」is not “How do I lower cortisol as far as possible?” but “Is the measurement reliable? Is the diurnal rhythm reasonable? How do symptoms, illness, medication, and context affect interpretation?”
單點唾液或血液數值很容易被採樣時間與急性事件影響。若有疑似內分泌疾病症狀，應由醫療專業人員選擇檢驗與解讀，不應用消費型壓力分數自行診斷。A single saliva or blood value is easily affected by sampling time and acute events. Suspected endocrine symptoms require clinician-selected testing and interpretation, not self-diagnosis from a consumer stress score.
一分鐘檢核One-minute check
「今天手錶顯示壓力高，所以我的皮質醇一定過高」有哪兩個問題？裝置指標未必直接測量皮質醇；即使有單點數值，也不能脫離時段與臨床情境解讀。What are two problems with “My watch showed high stress today, so my cortisol must be high”? A device metric may not directly measure cortisol, and even a single value cannot be interpreted apart from time and clinical context.
English companion—Week 2: performance, plasticity, and stress. Resistance training produces a stimulus; adaptation occurs during recovery. Working sets, load, exercise selection, proximity to failure, frequency, sleep, and nutrition jointly determine stimulus and fatigue. The episode’s high-intensity, low-volume approach is one case, not a novice prescription; reaching failure is not required for strength or hypertrophy, and general adult guidance is at least two days of muscle-strengthening activity weekly. Separate method (how you train), goal (strength, muscle, endurance, skill, or health), and outcome (long-term change rather than one bout of soreness). Neuroplasticity means that nervous-system connections and function can change after novelty, error, stress, or pharmacological exposure; attention and context select changes, and rest, sleep, and repetition help consolidate them. More plasticity alone does not establish benefit, safety, eligibility, or a care model. Cortisol is regulated by the hypothalamic-pituitary-adrenal axis and contributes to energy supply, immune signaling, vascular tone, and stress response. It normally varies across the day; both high and low values may matter. Interpret a measurement with timing, sampling method, acute events, illness, medication, and clinical context. Consumer stress scores are not a diagnosis.
5
第三週｜胜肽藥物與灰色市場Week 3: peptide medicines and the gray market
同樣叫peptide，監管與證據可以差數個層級。Items all called peptides can differ by several levels in regulation and evidence.
單元7｜五種狀態：核准、仿單外、調製、研究中、非法販售Module 7: five statuses—approved, off-label, compounded, investigational, and illegal sale
學完你能做到By the end, you can看到產品主張時，先把它放進正確的監管抽屜。When you see a product claim, place it in the correct regulatory drawer first.
| 狀態Status | 意思Meaning | 不能推論What it does not imply |
|---|---|---|
| 核准藥物Approved drug | 特定產品、適應症與標示的利益風險經監管審查。A regulator has reviewed benefit and risk for a specified product, indication, and labeling. | 不代表對所有人、所有目的都適合。It does not mean it suits everyone or every purpose. |
| 仿單外使用Off-label use | 醫療專業人員使用已核准藥物於未列入核准標示的情境。A clinician uses an approved drug in a situation not included in its approved label. | 不等於該用途已被FDA核准。It is not FDA approval of that use. |
| 調製藥物Compounded drug | 因個別醫療需求由合規藥局調製；本身不經FDA上市核准。Prepared by a compliant pharmacy for an individual medical need; it does not itself receive FDA marketing approval. | 不是學名藥，也不應宣稱與核准藥完全相同。It is not a generic and should not be claimed to be identical to an approved drug. |
| 研究中產品Investigational product | 在合規臨床試驗或IND架構下蒐集證據。Evidence is collected in a compliant clinical trial or under an IND framework. | 「正在研究」不等於有效。“Being studied” does not mean effective. |
| 非法／研究用販售Illegal or research-use sale | 可能以「非供人體使用」規避監管，卻實際對消費者宣稱療效。It may use “not for human use” to evade regulation while making consumer efficacy claims. | 標籤不是純度、身分或無菌證明。A label is not proof of purity, identity, or sterility. |
FDA明確指出，調製藥物未經FDA核准，上市前不審查其安全、有效與品質；它在特定醫療需求下可能有角色，但不是一般核准產品的自動替代品。[S4]The FDA explicitly notes that compounded drugs are not FDA-approved and do not receive premarket review of safety, effectiveness, and quality. They may have a role for a particular medical need, but are not automatic substitutes for ordinarily approved products.
一分鐘檢核One-minute check
「某診所向FDA註冊，所以它的胜肽都經FDA核准」正確嗎？不正確。機構註冊、產品列名與個別產品核准不是同一件事。Is “a clinic is registered with the FDA, so all its peptides are FDA-approved” correct? No. Facility registration, product listing, and approval of an individual product are different things.
單元8｜GLP-1：成熟證據仍需特定化Module 8: GLP-1—mature evidence still requires specificity
學完你能做到By the end, you can知道「有核准GLP-1藥物」不等於「任何GLP-1產品都一樣」。Know that “approved GLP-1 drugs exist” does not mean every GLP-1 product is the same.
GLP-1是腸泌素訊號；相關藥物可活化GLP-1受體，影響食慾、胃排空與葡萄糖調節。Semaglutide等產品已有特定核准用途，但正確判斷必須回到「哪個產品、哪個適應症、哪個劑型與哪份現行標示」。2026年Wegovy標示即是產品層級的權威資料，而不是社群簡圖。[S6]GLP-1 is an incretin signal; related medicines can activate the GLP-1 receptor and affect appetite, gastric emptying, and glucose regulation. Products including semaglutide have particular approved uses, but proper appraisal returns to which product, indication, dosage form, and current label. The 2026 Wegovy label is product-level authority, not a social-media graphic.
FDA另警告未核准或調製GLP-1產品可能涉及劑量換算錯誤、儲運、來源、仿冒與不同鹽型等問題；「含同一個熱門名稱」不能保證化學身分或品質相同。[S7]The FDA also warns that unapproved or compounded GLP-1 products may involve dose-conversion errors, storage, shipping, source, counterfeit, and salt-form problems; sharing a popular name cannot ensure the same chemical identity or quality.
G
閱讀順序：Reading order:產品身分→適應症→對照試驗→標示警語→替代方案→監測；不要從網路前後照直接跳到個人用藥決策。product identity → indication → controlled trials → label warnings → alternatives → monitoring. Do not jump from online before-and-after images to a personal medication decision.
一分鐘檢核One-minute check
「核准成分」與「核准產品」差在哪裡？產品還包括製造、純度、劑型、強度、標示與核准用途；只看到成分名稱仍不夠。What differs between an “approved ingredient” and an “approved product”? A product also includes manufacturing, purity, dosage form, strength, labeling, and approved use; the ingredient name alone is insufficient.
單元9｜GH軸、BPC-157、Epitalon與風險語言Module 9: the GH axis, BPC-157, Epitalon, and risk language
學完你能做到By the end, you can不被「修復、抗老、睡更深、零副作用」等模糊語言帶走。Avoid being carried away by vague language such as “repair,” “anti-aging,” “deeper sleep,” and “zero side effects.”
GH／IGF-1軸GH/IGF-1 axis
生長激素以脈衝方式釋放，受GHRH、somatostatin與ghrelin等訊號調節，並透過IGF-1等下游路徑產生作用與回饋。它不只關係到「長肌肉」，也牽涉代謝與多組織作用。[S9]Growth hormone is released in pulses, regulated by signals including GHRH, somatostatin, and ghrelin, and produces effects and feedback through downstream pathways including IGF-1. It involves metabolism and many tissues, not only “building muscle.”
灰色市場常見主張Common gray-market claims
BPC-157常被宣稱用於組織修復，Epitalon常被放入睡眠或抗老敘事；但FDA列出的公開安全資料指出，這些調製物質的人體安全資訊不足，並有免疫原性、聚集、雜質或API鑑別複雜度等疑慮。CJC-1295與ipamorelin也有各自的安全訊號與資料缺口。[S5]BPC-157 is often claimed for tissue repair and Epitalon is often placed in sleep or anti-aging narratives. FDA-listed public safety information finds inadequate human safety information for these compounded substances, with concerns including immunogenicity, aggregation, impurities, and complex API characterization. CJC-1295 and ipamorelin also have distinct safety signals and data gaps.
「沒有回報」“No reports”
可能表示監測系統不存在，不是副作用不存在。It may mean a surveillance system does not exist, not that side effects do not exist.
「人體自然存在」“Naturally present in the body”
外加版本、劑量、途徑、雜質與暴露時間仍可能不同。The externally supplied version, dose, route, impurities, and exposure duration can still differ.
「診所使用多年」“Used by clinics for years”
臨床慣例不等於有對照、可重複、長期追蹤的證據。Clinical custom is not evidence from controlled, replicable, long-term follow-up.
運動員另有規範Athletes face separate rules2026年WADA禁用清單S2涵蓋胜肽荷爾蒙、生長因子、相關物質與模擬物；醫療與運動禁藥判斷是不同問題。[S16]The 2026 WADA Prohibited List, S2, covers peptide hormones, growth factors, related substances, and mimetics; medical decisions and anti-doping determinations are different questions.
一分鐘檢核One-minute check
把「未發現傷害」改寫成更精確的句子：目前在特定用途與途徑下缺乏足夠安全資料，因此無法知道是否會對人造成傷害。Rewrite “no harms have been found” more precisely: there is currently insufficient safety information for the specified use and route, so we cannot know whether it harms people.
English companion—Week 3: peptide medicines and the gray market. An approved drug has regulatory review of benefit and risk for specified product, indication, and labeling; off-label use is use by a clinician outside approved labeling and is not FDA approval of that use. A compounded drug may be prepared by a compliant pharmacy for an individual medical need, but is not an FDA-approved generic and does not undergo the same premarket review. An investigational product collects evidence under a compliant trial or IND; research-use or illegal sales may use “not for human use” language while making consumer efficacy claims. GLP-1 medicines require product-specific appraisal: product, indication, dosage form, and current labeling. Unapproved or compounded GLP-1 products may involve dose-conversion errors, storage and shipping problems, source uncertainty, counterfeits, or different salt forms. The GH/IGF-1 axis is regulated by GHRH, somatostatin, ghrelin, and downstream feedback. For BPC-157, Epitalon, CJC-1295, and ipamorelin, limited human safety information, immunogenicity, aggregation, impurities, and characterization complexity remain material concerns. “No reports” can mean no surveillance, not no adverse events. WADA’s 2026 S2 list covers peptide hormones, growth factors, related substances, and mimetics.
6
第四週｜再生醫學、AI與決策Week 4: regenerative medicine, AI, and decisions
前沿不是「比較可靠」，而是「不確定性更高、驗證要求更嚴格」。Frontier does not mean “more reliable”; it means more uncertainty and stricter verification requirements.
單元10｜幹細胞與再生醫學：名稱不能替代產品身分Module 10: stem cells and regenerative medicine—a name cannot replace product identity
學完你能做到By the end, you can用四個問題拆解「幹細胞可修復關節」之類的主張。Use four questions to unpack claims such as “stem cells can repair joints.”
- 產品：Product:細胞從哪裡來？如何分離、培養、處理與鑑別？Where do cells come from, and how are they isolated, cultured, processed, and characterized?
- 用途：Use:聲稱治療哪個部位、疾病與嚴重程度？What body site, disease, and severity is claimed to be treated?
- 監督：Oversight:是否為核准產品，或有FDA監督的IND與IRB臨床試驗？Is it an approved product, or studied in an FDA-supervised IND and IRB clinical trial?
- 結果：Outcomes:看疼痛量表、影像、功能、手術率還是長期安全？Are pain scales, imaging, function, surgery rates, or long-term safety being assessed?
FDA消費者資訊指出，美國已核准的幹細胞產品限於由臍帶血取得的造血祖細胞，並用於影響造血系統的疾病；對常見骨科、神經與慢性疼痛等用途，許多市售再生醫學產品未經核准，且已有失明、腫瘤、感染與其他傷害報告。[S14]FDA consumer information states that US-approved stem-cell products are limited to cord-blood-derived hematopoietic progenitor cells for disorders affecting the hematopoietic system. Many marketed regenerative products for common orthopedic, neurological, and chronic-pain uses are unapproved, with reports of blindness, tumors, infection, and other harms.
一分鐘檢核One-minute check
ClinicalTrials.gov有登錄，是否代表產品經FDA核准？不是。試驗登錄、試驗監督與上市核准是不同狀態。Does a ClinicalTrials.gov listing mean a product is FDA-approved? No. Trial registration, trial oversight, and marketing approval are different statuses.
單元11｜AI與穿戴裝置：測量不等於意義Module 11: AI and wearables—measurement is not meaning
學完你能做到By the end, you can區分精密度、準確度、驗證與臨床意義。Distinguish precision, accuracy, validation, and clinical meaning.
| 問題Question | 要檢查什麼What to check |
|---|---|
| 它量得穩不穩？Is it measured consistently? | 相同條件重複測量的一致性。Agreement across repeated measurements under the same conditions. |
| 它量得準不準？Is it measured accurately? | 與可信參考標準的差距。The gap from a trusted reference standard. |
| 它適不適合這個人與用途？Is it suitable for this person and use? | 目標族群、配戴位置、活動情境與演算法版本。Target population, wear location, activity context, and algorithm version. |
| 數值是否改變醫療結果？Does the value change medical outcomes? | 是否能導向可證實有益的決策，而非只增加資料量。Whether it leads to decisions with demonstrable benefit rather than merely adding data. |
FDA對數位健康技術強調verification與validation：前者確認裝置是否以所需精度量到預定訊號，後者確認該訊號是否能在指定族群與用途下有意義地代表臨床事件。[S15]For digital health technologies, the FDA emphasizes verification and validation: the former asks whether a device measures its intended signal at the required precision, and the latter asks whether that signal meaningfully represents a clinical event for the specified population and use.
AI
第四個防錯規則：Fourth error-prevention rule:AI可以放大好資料，也可以快速放大偏差。模型輸出越精密，越需要追問資料來源、參考標準、漂移與決策後果。AI can amplify good data, and can also amplify bias quickly. The more precise the model output appears, the more you must ask about data source, reference standard, drift, and decision consequences.
一分鐘檢核One-minute check
睡眠戒指每天顯示REM分鐘數，能否直接證明某胜肽改善大腦恢復？不能；要先驗證睡眠分期準確性，再以適當對照排除其他因素，最後確認臨床重要結果。Can a sleep ring’s daily REM minutes directly prove that a peptide improves brain recovery? No. First validate sleep-stage accuracy, then use appropriate controls to exclude other factors, and finally confirm clinically important outcomes.
單元12｜把Podcast主張轉成安全決策Module 12: turn podcast claims into safe decisions
學完你能做到By the end, you can在不自行診療的前提下，把任何前沿健康主張轉成結構化問題。Without self-treating, turn any frontier-health claim into structured questions.
產品與用途Product and use
- 精確名稱、製造商、劑型與來源？Exact name, manufacturer, dosage form, and source?
- 核准適應症還是宣稱用途？Approved indication or claimed use?
- 是核准、仿單外、調製、研究中或非法販售？Approved, off-label, compounded, investigational, or illegally sold?
證據與效果Evidence and effect
- 證據最高到哪一層？What is the highest evidence level?
- 研究比較了什麼？What did the research compare?
- 改善的是替代指標還是重要臨床結果？Did it improve a surrogate marker or an important clinical outcome?
風險與品質Risk and quality
- 短期與長期傷害如何蒐集？How are short- and long-term harms collected?
- 產品身分、純度、無菌與儲運如何驗證？How are product identity, purity, sterility, and storage or shipping verified?
- 風險是否可逆？有哪些相互作用？Are risks reversible, and what interactions exist?
決策與替代Decision and alternatives
- 不做這項介入會怎樣？What happens if this intervention is not used?
- 有哪些證據較成熟的替代方案？Which alternatives have more mature evidence?
- 由誰監測？什麼條件下停止？Who monitors, and under what conditions do you stop?
紅旗Red flags宣稱「修復所有組織」「完全沒有副作用」「天然所以安全」「名醫自己也用」「研究用但附人體用量」「不需醫師與檢驗」「只有今天能買」時，應立即降低信任。Immediately lower trust when a claim says “repairs all tissue,” “no side effects at all,” “natural, therefore safe,” “a famous doctor uses it,” “research use with a human dose,” “no doctor or tests needed,” or “available today only.”
一分鐘檢核One-minute check
請任選影片中的一個主題，用上面12題寫出一頁判讀卡。若資料找不到，正確答案是「尚待驗證」，不是自行補空白。Choose one topic from the video and use the twelve questions above to write a one-page appraisal card. If information cannot be found, the correct answer is “awaiting verification,” not filling gaps by guesswork.
English companion—Week 4: regenerative medicine, AI, and decisions. Ask four questions of a stem-cell claim: what exactly is the product and how is it sourced, processed, and characterized; what body site, disease, and severity is it claimed to treat; is it an approved product or studied under FDA-supervised IND and IRB oversight; and which outcomes are measured—pain, imaging, function, surgery rates, or long-term safety? In the United States, approved stem-cell products are limited to cord-blood-derived hematopoietic progenitor cells for disorders affecting the hematopoietic system; many marketed regenerative products for orthopedic, neurological, or chronic-pain uses are unapproved, with reported harms including blindness, tumors, and infection. A trial listing is not FDA marketing approval. For AI and wearables, distinguish precision (repeatability), accuracy (agreement with a trusted reference), validation for the intended population and use, and whether a value changes a clinically beneficial decision. Verification asks whether a device measures the intended signal at the required accuracy; validation asks whether that signal meaningfully represents a clinical event in the specified use. Before acting on any frontier-health claim, identify the product and use, evidence and endpoint, risk and quality controls, alternatives, monitoring, stopping conditions, and red flags such as “repairs all tissue,” “no side effects,” “natural therefore safe,” “research use with a human dose,” or “today only.”
7
總測驗Final quiz
先完成作答，再點「顯示答案與解說」自行核對；此功能不依賴JavaScript。Answer first, then select “show answers and explanations” to check yourself; this function does not depend on JavaScript.
Final quiz—English version and answer explanations. 1. What does “this molecule is a peptide” most directly tell you? (A) It is proven to repair tissue. (B) It belongs to a class of amino-acid-chain molecules. (C) It is safer than a small-molecule drug. Answer B: peptide is a molecular classification, not evidence of efficacy or safety. 2. What best supports a general clinical causal conclusion? (A) A celebrity’s personal use. (B) Animal mechanism research. (C) Multiple replicable, high-quality controlled studies. Answer C: cases and mechanisms can generate hypotheses, while high-quality replicable human comparisons better support causation. 3. What is the best current description of training every set to failure? (A) Everyone needs it for muscle gain. (B) It is not required for progress in strength or hypertrophy. (C) It is useful for no one. Answer B: not necessary does not mean never useful; method, volume, goal, and person matter. 4. A single cortisol value most needs to be paired with (A) sampling time, method, and clinical context; (B) a social-media average; or (C) a wearable’s one-day stress score. Answer A: cortisol has a marked diurnal rhythm and is affected by acute events, illness, and medicines. 5. How do compounded drugs relate to generics? (A) Neither requires regulation. (B) Both are identical FDA-approved products. (C) Generics are approved; compounded drugs are not equivalent to FDA-approved generics. Answer C: compounding may serve specific medical needs but does not receive the same premarket safety, efficacy, and quality review. 6. The most reasonable reading of “no reported side effects” is (A) proof of safety; (B) first check whether surveillance, sample size, and follow-up were adequate; or (C) proof that effects exist only with other products. Answer B: absent reports may reflect absent monitoring. 7. After a wearable produces a precise sleep score, the next key question is whether it has been validated for this use and population—not whether its interface looks professional or its score has two decimals. 8. The best first step for a frontier-health claim is to establish product identity, use, evidence level, and regulatory status—not a purchase channel or celebrity dose.
8
核心術語表Core glossary
點開查看；英文放在括號內，方便回到原節目。Open each item to view it; English appears in parentheses for returning to the source episode.
胺基酸（amino acid）Amino acid
構成胜肽與蛋白質的基本單元；不同排列與修飾會形成不同分子功能。A basic unit of peptides and proteins; different sequences and modifications create different molecular functions.
胜肽（peptide）Peptide
由胺基酸連成的鏈。FDA在部分監管政策中以40個以下α-胺基酸作為操作邊界。A chain of amino acids. The FDA uses 40 or fewer α-amino acids as an operational boundary in some regulatory policies.
受體（receptor）Receptor
能辨識並回應特定分子訊號的蛋白質；位置、數量與下游路徑會影響效果。A protein that recognizes and responds to a particular molecular signal; location, number, and downstream pathways affect the result.
促效劑（agonist）Agonist
結合並活化受體的分子。GLP-1 receptor agonist即活化GLP-1受體的藥物類別。A molecule that binds and activates a receptor. A GLP-1 receptor agonist is a drug class that activates the GLP-1 receptor.
促分泌劑（secretagogue）Secretagogue
促使細胞或腺體釋放某種物質的分子；不表示它必然安全或只在目標位置作用。A molecule that prompts cells or glands to release a substance; this does not mean it is necessarily safe or acts only at the target location.
半衰期（half-life）Half-life
體內分子濃度下降一半所需時間；影響暴露與給藥間隔，但不是全部藥動學。The time required for a molecule’s concentration in the body to fall by half; it affects exposure and dosing interval but is not all of pharmacokinetics.
藥動學（pharmacokinetics, PK）Pharmacokinetics, PK
身體如何吸收、分布、代謝與排除藥物。How the body absorbs, distributes, metabolizes, and eliminates a drug.
藥效學（pharmacodynamics, PD）Pharmacodynamics, PD
藥物如何作用於身體，以及濃度與效應的關係。How a drug acts on the body and the relationship between concentration and effect.
免疫原性（immunogenicity）Immunogenicity
產品引發免疫反應的可能性；胜肽聚集、雜質或序列差異可能改變此風險。A product’s potential to provoke an immune response; peptide aggregation, impurities, or sequence differences may alter that risk.
GLP-1
glucagon-like peptide-1，一種腸泌素訊號；相關藥物可作用於GLP-1受體。Glucagon-like peptide-1, an incretin signal; related medicines can act at the GLP-1 receptor.
GH／IGF-1軸GH/IGF-1 axis
生長激素與類胰島素生長因子相關的調節系統，涉及生長、代謝與組織訊號。A regulatory system involving growth hormone and insulin-like growth factor, with growth, metabolic, and tissue signaling roles.
HPA axis
下視丘－腦下垂體－腎上腺軸，調節皮質醇與壓力反應。The hypothalamic-pituitary-adrenal axis, which regulates cortisol and stress responses.
神經可塑性（neuroplasticity）Neuroplasticity
神經系統依經驗、損傷或介入而改變連結與功能的能力；改變不必然有益。The nervous system’s capacity to change connections and function through experience, injury, or intervention; change is not inherently beneficial.
調製藥物（compounded drug）Compounded drug
為特定醫療需求而調製的藥物；不是FDA核准學名藥，上市前不接受相同審查。A drug prepared for a particular medical need; it is not an FDA-approved generic and does not receive the same premarket review.
IND
Investigational New Drug application，讓未核准產品在FDA監督架構下進入臨床研究的重要程序。An Investigational New Drug application, an important pathway for an unapproved product to enter clinical research under FDA oversight.
臨床終點（clinical endpoint）Clinical endpoint
直接反映病人感受、功能或存活等臨床結果的測量；與替代指標不同。A measure of clinical results such as how patients feel, function, or survive, unlike a surrogate marker.
Glossary—English definitions. Amino acid: a basic unit of peptides and proteins; different sequences and modifications create different molecular functions. Peptide: a chain of amino acids; the FDA uses 40 or fewer α-amino acids as an operational boundary in some policies. Receptor: a protein that recognizes and responds to a particular molecular signal. Agonist: a molecule that binds and activates a receptor. Secretagogue: a molecule that causes cells or glands to release a substance. Half-life: the time required for a molecule’s concentration in the body to fall by half. Pharmacokinetics (PK): how the body absorbs, distributes, metabolizes, and eliminates a drug. Pharmacodynamics (PD): how a drug acts on the body and the relationship between concentration and effect. Immunogenicity: a product’s potential to provoke an immune response. GLP-1: glucagon-like peptide-1, an incretin signal; related medicines can act at the GLP-1 receptor. GH/IGF-1 axis: the growth-hormone and insulin-like growth-factor regulatory system. HPA axis: the hypothalamic-pituitary-adrenal axis, which regulates cortisol and stress responses. Neuroplasticity: the nervous system’s ability to change connections and function through experience, injury, or intervention; change is not inherently beneficial. Compounded drug: a drug prepared for a specific medical need; it is not an FDA-approved generic and does not receive the same premarket review. IND: Investigational New Drug application, a key pathway for studying an unapproved product under FDA oversight. Clinical endpoint: a measure that directly reflects how a patient feels, functions, or survives, unlike a surrogate marker.
✎
我的學習筆記My learning notes
可直接輸入；一般瀏覽器會嘗試保存在本機，iPhone檔案預覽器不一定保留，重要內容請另行複製。You can type directly; most browsers try to retain notes locally, while the iPhone file preview may not, so copy important content elsewhere.
9
來源與證據說明Sources and evidence notes
優先使用官方節目頁、監管機關、政府指引與同儕審查文獻。查閱日期：2026-08-02。Official programme pages, regulators, government guidance, and peer-reviewed literature are prioritized. Accessed: 2026-08-02.
- Dr. Andrew Huberman—Peptides, Performance, and Protocols原始節目The Tim Ferriss Show影片；用於確認節目身分、長度與章節。Original programme. The Tim Ferriss Show video, used to confirm episode identity, duration, and chapters.
- The Tim Ferriss Show Transcripts: Dr. Andrew Huberman—Peptides, Performance, and Protocols (#876)官方逐字稿用於主題定位與事實核對；本文件未重製或逐句翻譯該逐字稿。Official transcript. Used for topic location and fact checking; this document does not reproduce or translate it line by line.
- FDA MAPP 5016.3—Quality Assessment of Products Containing Peptide or Protein Drug Substances官方政策胜肽的監管操作定義，以及胜肽／蛋白質藥品品質評估的職責界線。Official policy. It covers the operational regulatory definition of peptides and quality-assessment responsibilities for peptide and protein medicines.
- FDA—Understanding the Risks of Compounded Drugs官方監管調製藥物不經FDA上市核准，及其品質與污染風險。Official regulation. Compounded drugs do not receive FDA marketing approval and can pose quality and contamination risks.
- FDA—Certain Bulk Drug Substances That May Present Significant Safety Risks官方監管BPC-157、Epitalon、CJC-1295、Ipamorelin等物質的資料缺口與潛在安全疑慮。Official regulation. It describes data gaps and potential safety concerns for BPC-157, Epitalon, CJC-1295, Ipamorelin, and related substances.
- FDA—WEGOVY (semaglutide) 2026 Prescribing Information核准標示以產品層級理解GLP-1受體促效劑的適應症、風險與使用條件。Approved label. Used for product-level understanding of GLP-1 receptor agonist indications, risks, and conditions of use.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss官方警示未核准、調製、仿冒、不同鹽型、儲運與劑量錯誤。Official warning. It covers unapproved, compounded, and counterfeit products, different salt forms, storage and shipping, and dosing errors.
- Physical Activity Guidelines for Americans—Top 10 Things to Know政府指引一般成人每週活動與肌力訓練基準。Government guidance. It provides weekly activity and muscle-strengthening baselines for adults.
- Endotext—Normal Physiology of Growth Hormone in Normal Adults學術綜述GH、GHRH、somatostatin、ghrelin與IGF-1回饋系統。Academic review. It describes the GH, GHRH, somatostatin, ghrelin, and IGF-1 feedback system.
- Effects of Resistance Training Performed to Repetition Failure or Non-Failure系統性回顧統合分析顯示，力竭並非肌力與肌肥大進步的必要條件。Systematic review. Its meta-analysis finds failure is not required for strength or hypertrophy progress.
- NCBI Bookshelf—Physiology, Cortisol臨床綜述皮質醇生理功能、HPA axis與日夜節律。Clinical review. It covers cortisol physiology, the HPA axis, and diurnal rhythm.
- FDA—Psychedelic Drugs: Considerations for Clinical Investigations2026最終指引迷幻藥物臨床試驗的安全、盲法、心理支持、劑量反應與持久性考量。2026 final guidance. It covers safety, blinding, psychological support, dose response, and durability in psychedelic-drug clinical trials.
- NIDA—Psychedelic and Dissociative Drugs政府研究機構研究現況、心理與生理作用，以及醫療情境外使用的風險。Government research institute. It describes current research, psychological and physiological effects, and risks of use outside medical settings.
- FDA—Important Patient and Consumer Information About Regenerative Medicine Therapies官方警示未核准幹細胞與再生醫學產品的用途誤導及已知傷害。Official warning. It covers misleading uses and known harms associated with unapproved stem-cell and regenerative-medicine products.
- FDA—Digital Health Technologies: Verification and Validation官方指引說明穿戴裝置與數位終點的verification、validation與fit-for-purpose原則。Official guidance explanation. It discusses verification, validation, and fit-for-purpose principles for wearables and digital endpoints.
- WADA—2026 Prohibited List運動規範2026年禁用物質與方法清單；S2涵蓋胜肽荷爾蒙、生長因子與相關物質。Sport regulation. The 2026 prohibited substances and methods list; S2 covers peptide hormones, growth factors, and related substances.
Sources and evidence notes—English version. S1 is the original Tim Ferriss Show video, used to confirm episode identity, length, and chapters. S2 is the official transcript, used for topic location and fact checking; this course does not reproduce or translate it line by line. S3 is FDA MAPP 5016.3, covering the operational regulatory definition of peptides and the scope of quality assessment for peptide and protein drug products. S4 explains that compounded drugs do not receive FDA marketing approval and discusses quality and contamination risk. S5 discusses information gaps and potential safety concerns for BPC-157, Epitalon, CJC-1295, Ipamorelin, and similar substances. S6 is the 2026 Wegovy prescribing information, used for product-level understanding of GLP-1 receptor agonist indications, risks, and conditions of use. S7 covers unapproved and compounded GLP-1 products, counterfeits, salt forms, storage, and dose errors. S8 provides general adult activity and muscle-strengthening baselines. S9 reviews GH, GHRH, somatostatin, ghrelin, and IGF-1 feedback. S10 is a systematic review finding that training to failure is not necessary for strength and hypertrophy progress. S11 reviews cortisol physiology, the HPA axis, and diurnal rhythm. S12 is the 2026 FDA final guidance on psychedelic clinical investigations, including safety, blinding, psychological support, dose response, and durability. S13 is NIDA material on psychedelic and dissociative drugs, including current research and risks outside medical settings. S14 warns about misleading claims and known harms from unapproved stem-cell and regenerative-medicine products. S15 explains verification, validation, and fit-for-purpose principles for wearables and digital endpoints. S16 is the 2026 WADA Prohibited List; S2 includes peptide hormones, growth factors, and related substances. These sources prioritize official programme pages, regulators, government guidance, and peer-reviewed literature; the access date is 2026-08-02.
證據限制：節目本身主要是長篇訪談，含個人經驗、推論與前沿主張；本教材只把它當作學習入口。監管狀態與產品標示可能更新，做真實醫療或競賽決策前應重新查核當日官方資料。Evidence limitation: the episode itself is principally a long-form interview containing personal experience, inference, and frontier claims; this course uses it only as a learning entry point. Regulatory status and product labeling can change, so consult current official materials before making an actual medical or competition decision.